Search the Newsreel

Sanara MedTech Inc. (SMTI) Tops Q2 Earnings Estimates

Sanara MedTech Inc. (SMTI) reported Q2 earnings of $0.05 per share, significantly beating the Zacks Consensus Estimate of $0.02, representing a 150% surprise. Despite missing revenue estimates at $28.14 million, the company's shares have gained 46.7% year-to-date. SMTI currently holds a Zacks Rank #3 …

Sanara MedTech (NASDAQ:SMTI) Issues Quarterly Earnings Results, Misses Expectations By $0.03 EPS

Sanara MedTech Q2 Results: Sales Rise 9% YoY, EPS Misses Estimate

Sanara Medtech earnings missed by $0.02, revenue fell short of estimates

Sanara MedTech (SMTI) grows H1 2026 revenue to $55.9M and trims loss

Sanara MedTech Inc. (SMTI) reported significant revenue growth for the first half of 2026, reaching $55.9 million, primarily driven by strong sales of its soft tissue repair products. The company also substantially reduced its net loss attributable to shareholders, nearly breaking even with a …

Sanara MedTech Inc. Q2 2026: Revenue $28.14M, EPS $(0.05) — 10-Q Summary

Sanara MedTech Inc. reported its Q2 2026 financial results, with revenue reaching $28.14M, a 9.1% increase year-over-year. The company posted a diluted loss per share of $(0.05), an improvement from $(0.23) in Q2 2025. This growth was primarily driven by surgical soft tissue repair …

Sanara MedTech Inc. (SMTI) Releases Q2 2026 Earnings: Revenue Rises 8.9%

Sanara MedTech Inc. (SMTI) reported an 8.9% increase in revenue for Q2 2026, reaching $28.1 million, with gross profit rising to $26.2 million. Despite strong top-line growth, the company posted a net loss of $(0.05) per diluted share. The article also details hedge fund …

Sanara MedTech (SMTI) grows revenue, posts Q2 loss amid pending MIMEDX deal

Form 8K Sanara Medtech Inc For: 11 August By Investing.com

This article reports on the filing of a Form 8K by Sanara Medtech Inc. on August 11, 2026. The brief announcement from Investing.com indicates this as a significant event for shareholders and market watchers of SMTI.

MIMEDX Expected to Acquire Sanara MedTech, Pending Closing Conditions

Sanara MedTech reported a 9% increase in Q2 2026 net revenue to $28.1 million and a 14% rise for the first six months to $55.9 million, maintaining a 93% gross margin. The company also announced a signed agreement for its acquisition by MIMEDX, pending …

Sanara MedTech (SMTI) Expected to Post Earnings on Wednesday

Bronstein, Gewirtz & Grossman, LLC Encourages Sanara MedTech Inc. (SMTI) Shareholders to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Sanara MedTech Inc. (SMTI) on behalf of investors. This investigation follows a 24.7% stock price drop on November 12, 2026, after Sanara announced the discontinuation of its Tissue Health Plus program, incurring a $26.5 …

Sanara MedTech (NASDAQ:SMTI) Stock Rating Lowered by Freedom Capital

Freedom Capital downgraded Sanara MedTech (NASDAQ:SMTI) from "strong buy" to "hold," aligning with several other recent rating cuts for the company. The current analyst consensus is "Reduce," with a $35.00 price target, and SMTI is trading near its 52-week high at $34.00. Institutional investors, …

Sanara MedTech Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sanara MedTech Inc. - SMTI

Kahn Swick & Foti, LLC (KSF) is investigating the proposed sale of Sanara MedTech Inc. (SMTI) to MiMedx Group, Inc. (MDXG). KSF is examining whether the offered consideration of $33.00 in cash and 0.4735 shares of MiMedx common stock per Sanara share undervalues the …

Sanara MedTech (NASDAQ:SMTI) Downgraded by Wall Street Zen to Buy

Sanara MedTech Inc. (SMTI) filer’s amended 13G shows exit from share ownership

An amended Schedule 13G filing for Sanara MedTech Inc. (SMTI) indicates that investment advisor Christopher M. Plahm, along with Tall Pines Capital, LLC, and Stonebridge Wealth Management, LLC, no longer beneficially own shares in the company. The filing reports 0 shares owned, representing 0.0% …

SANARA MEDTECH INC : H.C. WAINWRIGHT CUTS TO NEUTRAL FROM BUY; CUTS TARGET PRICE TO $35 FROM $36

H.C. Wainwright has downgraded SANARA MEDTECH INC (SMTI.O) from a "Buy" rating to "Neutral" and simultaneously lowered its target price to $35 from $36. This change in rating and price target reflects the analyst's updated view on the company's prospects. The article reiterates this …

Is There Now An Opportunity In Sanara MedTech Inc. (NASDAQ:SMTI)?

Sanara MedTech Inc. (SMTI) has seen a significant share price rise and its stock is currently undervalued according to Simply Wall St's valuation model, trading below its intrinsic value of $44.08. The company's earnings are expected to double in the coming years, indicating a …

Shareholder Alert: Ademi LLP investigates whether Sanara MedTech Inc. is obtaining a Fair Price for Public Shareholders

Ademi LLP is investigating Sanara MedTech Inc. (Nasdaq: SMTI) regarding its transaction with MiMedx, examining whether public shareholders are receiving a fair price and if the Sanara board fulfilled its fiduciary duties. The investigation focuses on the $35 per share cash-and-stock deal, insider benefits, …

Sanara MedTech to Be Acquired by MiMedx in $35-Per-Share Cash-and-Stock Merger

Sanara MedTech is set to be acquired by MiMedx in a cash-and-stock merger, valuing Sanara at approximately $35 per share. The deal aims to combine two wound-care businesses and is supported by a concurrent voting agreement from holders of about 38.9% of Sanara's voting …

MiMedx Group (SMTI) details Sanara MedTech buyout and 2027 profit goals

SMTI Stock Alert: Halper Sadeh LLC is Investigating Whether Sanara MedTech Inc. is Obtaining a Fair Price for its Shareholders

Halper Sadeh LLC, an investor rights law firm, is investigating the proposed sale of Sanara MedTech Inc. (SMTI) to MiMedx Group, Inc. and is encouraging Sanara shareholders to examine their rights and options. The investigation focuses on whether Sanara's board failed to secure the …

MiMedx Group Q2 Earnings Call Highlights

Key Points Interested in MiMedx Group, Inc? Here are five stocks we like better. MiMedx agreed to acquire Sanara MedTech for $35 per share, adding more than $100 million in surgical revenue and approximately $4 billion in addressable market opportunity. The combined company expects …

MiMedx plans Sanara MedTech (SMTI) acquisition and prepares S-4 filing

MiMedx has announced its intention to acquire Sanara MedTech, aiming to create a larger regenerative medicine platform with a broader product portfolio for wound care and surgical applications. The acquisition is expected to close by year-end, pending customary closing conditions and regulatory approval. MiMedx …

MIMEDX to acquire Sanara MedTech for $350 million

MiMedx Group Inc. announced its definitive merger agreement to acquire Sanara MedTech Inc. for approximately $350 million. Sanara shareholders will receive $33.00 in cash and 0.4735 shares of MIMEDX common stock per share, representing a 46% premium to Sanara's 30-day volume-weighted average share price. …

MIMEDX Announces Second Quarter 2026 Operating & Financial Results

Reports Second Quarter Net Sales of $64 Million Reiterates Full Year Financial Outlook on a Standalone Basis Announces Plans to Acquire Sanara MedTech Management to Host Conference Call Today, July 29, 2026, at 4:30 PM ET MARIETTA, Ga., July 29, 2026 (GLOBE NEWSWIRE) -- …

MiMedx agrees to buy Sanara MedTech for $35 a share (SMTI:NASDAQ)

MiMedx has announced an agreement to acquire Sanara MedTech for $35 per share. The deal will provide Sanara shareholders with $33.00 in cash and 0.4735 shares of MiMedx common stock for each share they own. This acquisition represents a significant merger in the medical …

Sanara MedTech Inc. Revenue Breakdown – NASDAQ:SMTI

Sanara MedTech Inc. (NASDAQ:SMTI) generated $103.12 million in revenue last year, with its Soft Tissue Repair Products segment contributing the most at $91.35 million. The United States was the primary geographic contributor, accounting for the entire $103.12 million in revenue, an increase from $86.67 …

Sanara Medtech Inc (SMTI) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Sanara Medtech Inc (SMTI), providing a breakdown of major shareholders including FA Sanara, L.L.C., Tall Pines Capital LLC, and BlackRock Institutional Trust Company, N.A. It also categorizes shareholders by type (e.g., corporation, individual investor) and presents institutional …

Sanara Medtech Inc (SMTI) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Sanara Medtech Inc (SMTI) concerning its dividend and stock split history. It states that the company has distributed a total of $0.00 in dividends over the past five years and indicates that there is no historical data available …

Sanara Medtech Inc (SMTI) Financial Health: Profitability & Balance Sheet Analysis

Sanara Medtech Inc (SMTI) currently holds a financial score of 7.31, ranking 117 out of 155 in the pharmaceuticals industry, indicating stable financial health and high operating efficiency. The company reported a significant year-over-year revenue increase of 18.62% to $27.80 million, and its net …

Sanara Medtech Inc (SMTI) Institutional Confidence

Sanara Medtech Inc (SMTI) currently holds an institutional shareholding score of 3.00, placing it 92nd out of 155 companies in the Pharmaceuticals industry. The institutional shareholding proportion has increased by 18.63% quarter-over-quarter to 15.50%. James Simons is the largest institutional shareholder, holding 0.71% of …

Sanara MedTech stock trades steady as advanced wound care growth supports valuation

Sanara MedTech (SMTI) stock trades steadily, backed by robust growth in the advanced wound care sector. The company focuses on specialized products for surgical and chronic wound management within the U.S. healthcare market, showing consistent double-digit revenue expansion and strategic investments in sales and …